In Massachusetts, Audax Medical, Inc. has a worldwide license from Northeastern University for new nanotechnology of a self-assembling arginine-rich peptide to add to its current tissue regeneration platform. They plan to use this new nanotech for their medical applications and tissue regeneration. The newly developed nanostructures have antimicrobial properties, but unlike antibiotics which go after specific cellular activity, the nanoparticles aim specifically for the microorganisms’ cytoplasmic membrane which limits the inflammation and infection in surrounding tissue. Mark Johanson, Audax’s CEO, told PR Newswire, “We are excited to be collaborating with Northeastern’s team of world-class researchers. This technology fits perfectly with our company’s core biologics platform, while expanding potential clinical opportunities in the growing Wound Care and Anti-Infection markets.”
Latest article
Pineapple pact shows fruits of collaboration on Earth Day
In California, Dole Packaged Foods has partnered with circular design firm Rais Case and Ananas Anam, creator of pineapple-based textile Piñatex®, to tackle pineapple...
Project converting chicken feathers into cultivated chicken meat concludes first phase
In Italy, a research project looking to grow cells from chicken feathers into chicken meat has concluded its first phase by generating a batch...
Vote for sustainability: Bioplastic dummy ballots used to spread voter awareness
In India, IIT Guwahati has developed 3D-printed dummy ballots made of biobased polylactic acid.
Commissioned by the Systematic Voters' Education and Electoral Participation Cell, the...